Research programme: toxoplasmosis therapeutics - Turing Pharmaceuticals

Drug Profile

Research programme: toxoplasmosis therapeutics - Turing Pharmaceuticals

Alternative Names: CDPK1 Inhibitor - Turing Pharmaceuticals; DHFR Inhibitor - Turing Pharmaceuticals; TRP 004; TRP 012; TRP 013; TUR 006

Latest Information Update: 07 Oct 2016

Price : $50

At a glance

  • Originator Turing Pharmaceuticals
  • Class Antiparasitics; Small molecules
  • Mechanism of Action ATCDPK1 protein inhibitors; Tetrahydrofolate dehydrogenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Toxoplasmosis

Highest Development Phases

  • Preclinical Toxoplasmosis

Most Recent Events

  • 04 Oct 2016 Turing Pharmaceuticals and Washington University in St. Louis agree to co-develop toxoplasmosis therapeutics for toxoplasmosis
  • 28 Nov 2015 Research programme: Dihydrofolate reductase inhibitors - Turing Pharmaceuticals is available for licensing in World as of 12 Nov 2015. http://www.turingpharma.com/
  • 12 Nov 2015 Preclinical trials in Toxoplasmosis in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top